Choosing the right modality to address the solid tumor challenge

Solid tumors present unique hurdles, including heterogeneous microenvironments, delivery constraints, and immunologic resistance. This spotlight session outlines how developers can evaluate therapeutic modalities based on mechanism of action, translational fidelity, and feasibility for early clinical studies.

Key takeaways

• Compare modality characteristics relevant to targeting and penetrating solid tumors
• Align mechanism of action with tumor biology and anticipated human responses
• Assess implications for dose selection, safety margins, and biomarker strategy
• Evaluate manufacturing and delivery constraints that impact predictive validity
• Apply structured frameworks to inform modality selection for early clinical advancement